Arizona State University, Tempe, AZ, 3 Division of Pulmonology, Phoenix Children's Hospital, Phoenix, AZ. RATIONALE: Under homeostatic conditions and in disease progression eosinophils have a variety of effector functions regulating Local Immunity And/or Remodeling/Repair (LIAR hypothesis). These activities are manifestations of different eosinophil subtypes, which, in turn, depend on the cytokine milieu of the tissue microenvironment. Eosinophil subtypes are characterized by expression of specific genes and we hypothesize that their functions are supported by a distinct metabolic phenotype. The goal of this study was to examine relationships between Th1 or Th2 cytokine-dependent gene expression and parameters of energy metabolism in mouse eosinophils. METHODS: Eosinophils from IL-5 overexpressing transgenic mice (NJ1638) were purified to >98% purity and cultured in cytokine cocktails typical for Th1 or Th2 environment to polarize the cells to their subtypes (E1 and E2). RNA was extracted for RNA-seq transcriptome analysis and mitochondrial function was assessed by measuring the relative uptake of MitoTracker Orange (potential dependent) to MitoTracker Far Red (potential independent). Rates of oxygen consumption and extracellular acidification were directly assessed in polarized eosinophils using a Seahorse XFe96 Analyzer. RESULTS: RNA-seq analysis showed elevated expression of genes present in mitochondrial respiratory chain in Th2 compared to Th1 cytokine treated eosinophils. Consistent with these observations E2 eosinophils had a higher inner mitochondrial membrane potential. E2 eosinophils had significantly higher maximal respiratory capacity and rate of media acidification compared to E1 eosinophils. CONCLUSIONS: Our studies showed an overall elevated metabolic rate in Th2 cytokine treated eosinophils (E2 eosinophils), suggesting a link between eosinophil subtypes and parameters of their energy metabolism. The HEROES study evaluated RPC4046 in adults with active eosinophilic esophagitis (EoE). We conducted pre-specified and post-hoc analyses to assess RPC4046 in steroid-refractory subjects. METHODS: Adults with EoE (n599) were stratified by steroid-refractory status (determined by prior corticosteroid use and investigator judgment) and randomized 1:1:1 to RPC4046 360 mg (n517), 180 mg (n514), or placebo (n516) weekly for 16 weeks. The primary endpoint was change from baseline in mean esophageal eosinophil counts at week 16. Secondary endpoints included mean change from baseline to week 16 in EoE Endoscopic Reference Score (EREFS), improvements in dysphagia (Daily Symptom Diary [DSD]), Eosinophilic Esophagitis Activity Index (EEsAI) score, and EoE histology scoring system (EoEHSS) per grade and stage. RESULTS: At week 16, compared with placebo, each dose group showed significant improvements in mean esophageal eosinophil counts (P< _0.0001), EREFS (P<0.005), and histology (EoEHSS) (P<0.05), and a significantly greater proportion of patients had peak eosinophil counts <15 per high-power field (P<0.01). In the 360 mg group, compared with placebo, symptom severity (EEsAI) improved (P<0.05), while the mean change in DSD composite score approached significance (P50.055). The most frequently reported adverse events in the overall study were headache, upper respiratory tract infection, arthralgia, nasopharyngitis, diarrhea, and nausea. CONCLUSIONS: Compared with placebo, RPC4046 improved mean and peak eosinophil counts, histopathologic parameters, endoscopic features, and symptoms in steroid-refractory EoE patients, providing support that, in this subpopulation, RPC4046 markedly improves multiple measures used to evaluate EoE. In the overall study population, RPC4046 was generally safe and well tolerated.
